https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25573 Wed 22 Mar 2023 16:22:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27946 Wed 22 Mar 2023 16:18:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45228 Thu 27 Oct 2022 12:21:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34467 -1.min^-1) underwent a clinical evaluation of known risk factors by a physician and comprehensive laboratory analysis of immune responses both at rest and after two cycling ergometer tests: 60 min at 65% VO₂max (LONG); and 6 x 3 min intervals at 90% VO₂max (INTENSE). Blood tests were performed to determine Epstein Barr virus (EBV) status and DNA was genotyped for a panel of cytokine gene polymorphisms. Saliva was collected for measurement of IgA and detection of EBV DNA. Athletes were then followed for 9 months for self-reported episodes of respiratory illness, with confirmation of the underlying cause by a sports physician. There were no associations with risk of respiratory illness identified for any parameter assessed in the clinical evaluations. The laboratory parameters associated with an increased risk of respiratory illnesses in highly-trained athletes were cytokine gene polymorphisms for the high expression of IL-6 and IFN-γ expression of EBV-DNA in saliva; and low levels of salivary IgA concentration. A genetic risk score was developed for the cumulative number of minor alleles for the cytokines evaluated. Athletes prone to recurrent respiratory illness were more likely to have immune disturbances that allow viral reactivation, and a genetic predisposition to pro-inflammatory cytokine responses to intense exercise.]]> Thu 14 Mar 2019 16:50:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2000 Sat 24 Mar 2018 08:28:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17318 Sat 24 Mar 2018 08:01:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19172 Sat 24 Mar 2018 07:52:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19171 Sat 24 Mar 2018 07:52:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26990 in vivo, these might contribute to increased incidences of hospitalisations for infectious diseases among Indigenous women.]]> Sat 24 Mar 2018 07:25:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22115 Alloiococcus otitidis has been identified in specimens from patients with chronic otitis media with effusion. Whereas most of those studies employed molecular techniques, we used minor modifications of conventional microbiological methods to isolate and identify A. otitidis in samples obtained from 20/50 (40%) children referred for myringotomy. Alloiococcus otitidis was isolated from 10/22 (45%) Indigenous and 10/28 (36%) non-Indigenous children. This is the first report of isolation of A. otitidis from Australian children with chronic otitis media. All isolates were sensitive to penicillin, but 14/20 (70%) of the isolates were resistant or partially resistant to erythromycin as assessed by the E-test.]]> Sat 24 Mar 2018 07:13:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23765 Sat 24 Mar 2018 07:11:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48606 Fri 31 Mar 2023 08:37:25 AEDT ]]>